WO2023080102A1 - 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キット、及び脳内のアミロイドβの蓄積レベルを評価する方法 - Google Patents
血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キット、及び脳内のアミロイドβの蓄積レベルを評価する方法 Download PDFInfo
- Publication number
- WO2023080102A1 WO2023080102A1 PCT/JP2022/040614 JP2022040614W WO2023080102A1 WO 2023080102 A1 WO2023080102 A1 WO 2023080102A1 JP 2022040614 W JP2022040614 W JP 2022040614W WO 2023080102 A1 WO2023080102 A1 WO 2023080102A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amyloid
- brain
- exosomes
- derived
- bound
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 283
- 210000004556 brain Anatomy 0.000 title claims abstract description 206
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 192
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 192
- 238000000034 method Methods 0.000 title claims abstract description 85
- 210000004369 blood Anatomy 0.000 title claims abstract description 45
- 239000008280 blood Substances 0.000 title claims abstract description 45
- 238000009825 accumulation Methods 0.000 title claims abstract description 18
- 238000001514 detection method Methods 0.000 title claims description 79
- 239000000126 substance Substances 0.000 claims abstract description 146
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 125
- 230000027455 binding Effects 0.000 claims abstract description 25
- 210000002569 neuron Anatomy 0.000 claims description 179
- 230000009870 specific binding Effects 0.000 claims description 120
- 239000000090 biomarker Substances 0.000 claims description 108
- 238000003776 cleavage reaction Methods 0.000 claims description 10
- 238000011156 evaluation Methods 0.000 claims description 10
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical group O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 230000007082 Aβ accumulation Effects 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 62
- 239000007788 liquid Substances 0.000 description 61
- 238000006243 chemical reaction Methods 0.000 description 47
- 108020004707 nucleic acids Proteins 0.000 description 37
- 102000039446 nucleic acids Human genes 0.000 description 37
- 239000000523 sample Substances 0.000 description 37
- 239000000758 substrate Substances 0.000 description 33
- 238000007789 sealing Methods 0.000 description 32
- 239000011324 bead Substances 0.000 description 21
- 239000002245 particle Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000005259 measurement Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 210000005013 brain tissue Anatomy 0.000 description 14
- 102000004150 Flap endonucleases Human genes 0.000 description 12
- 108090000652 Flap endonucleases Proteins 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000009545 invasion Effects 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 9
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 239000003431 cross linking reagent Substances 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000003100 immobilizing effect Effects 0.000 description 5
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- -1 saliva Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 229920005992 thermoplastic resin Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical group C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 101150031224 app gene Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102000046783 human APP Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/682—Signal amplification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
Definitions
- the present invention provides a method for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood, a kit for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood, and evaluating the accumulation level of amyloid ⁇ in the brain. on how to.
- This application claims priority based on Japanese Patent Application No. 2021-180612 filed in Japan on November 4, 2021, the contents of which are incorporated herein.
- Alzheimer's disease is the dementia with the largest number of patients, and Alzheimer's disease accounts for 50-75% of all dementia, and treatment methods are currently being developed.
- amyloid ⁇ forms a polymer outside the brain nerve cells, accumulates in the brain, and deposits in the brain to form senile plaques. It is thought to be caused by the degeneration of nerves due to the formation of neurofibrils, which are oxidized to form filaments and deposited in the brain, causing neurological disorders such as neuronal cell death and synaptic dysfunction. .
- amyloid ⁇ For the treatment or prevention of Alzheimer's disease, it is effective to treat or prevent the accumulation of amyloid ⁇ before the tau-dependent neuropathy in the brain is caused.
- a method that can measure amyloid ⁇ in the brain is required, but the cerebrospinal fluid test currently used to measure amyloid ⁇ is highly invasive, and PET imaging and blood amyloid ⁇ can be measured.
- the method of detection by mass spectrometry requires special equipment.
- Exosomes are a type of extracellular vesicle, and are membrane vesicles with a diameter of about 40-150 nm that are secreted from cells. In recent years, it has been pointed out that exosomes may play a role in transmitting information to distant cells and tissues. Exosomes contain various proteins, lipids, and nucleic acids, and are thought to cause functional and physiological changes when transported to different cells.
- Non-Patent Document 1 reports that amyloid ⁇ binds to ganglioside GM1 present on the surface of exosomes in neurons, amyloid ⁇ is transported by exosomes, and accumulates in the brain to form plaques.
- Non-Patent Document 2 reports that amyloid ⁇ was detected in exosomes isolated from the plasma of Alzheimer's patients.
- nucleic acids such as DNA and RNA are quantified by real-time PCR or the like.
- Non-Patent Document 3 describes a technique of performing an enzymatic reaction in a large number of microcompartments and detecting fluorescence signals. This technique is called digital metrology.
- the sample solution is divided into an extremely large number of minute solutions. Then, the signal from each minute solution is binarized, only the presence or absence of target molecules is determined, and the number of target molecules is counted. Digital measurement can dramatically improve detection sensitivity and quantification compared to conventional real-time PCR methods and the like.
- Non-Patent Document 3 discloses a method using micro-sized droplets formed so that each well has a volume of several nanoliters.
- ICA digital Invasive Cleavage Assay
- Non-Patent Document 1 detects amyloid ⁇ bound to exosomes released from cultured neurons, but this detection method isolates exosomes released from cultured neurons and extracts amyloid ⁇ bound to exosomes. It is a method of immunostaining and detecting using an electron microscope, and is not a method of rapidly detecting amyloid ⁇ bound to exosomes derived from brain nerve cells in blood.
- Non-Patent Document 2 also detects amyloid ⁇ in exosomes isolated from plasma, and is not a rapid detection method. Moreover, it is not known to evaluate the accumulation level of amyloid ⁇ in the brain by detecting amyloid ⁇ bound to exosomes in blood.
- the present invention has been made in view of the circumstances described above, and includes a technique for rapidly and highly sensitively detecting amyloid ⁇ bound to exosomes derived from brain neurons, and a technique for evaluating the accumulation level of amyloid ⁇ in the brain. intended to provide
- the present invention includes the following aspects.
- a method for detecting amyloid ⁇ bound to exosomes derived from brain nerve cells in blood wherein amyloid ⁇ bound to exosomes derived from brain nerve cells in blood and labeled with a nucleic acid fragment, specific to amyloid ⁇ and a step of detecting the amyloid ⁇ -specific binding substance.
- the detection method according to [1] comprising the step of detecting biomarkers present on the surface of exosomes derived from the brain nerve cells.
- a method for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood comprising a biomarker present on the exosome surface and a biomarker present on the exosome surface labeled with a nucleic acid fragment Specifically binds to the exosome surface biomarker specific binding substance, a step of binding, detecting amyloid ⁇ bound to exosomes derived from brain neurons in the blood, and the exosome surface biomarker and detecting a specific binding substance.
- the amyloid ⁇ is bound to a biomarker present on the surface of exosomes derived from the brain nerve cells, [1] to the detection method according to any one of [3].
- the step of detecting the biomarker or the amyloid ⁇ is performed by capturing exosomes derived from the brain nerve cells using a substance that specifically binds to the biomarker or the amyloid ⁇ , [2 ] The detection method according to any one of [4]. [6] The detection method according to any one of [1] to [5], wherein the amyloid ⁇ -specific binding substance is an antibody or antibody fragment that specifically binds to amyloid ⁇ . [7] The detection method according to any one of [2] to [6], wherein the biomarker is ganglioside GM1.
- a kit for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood comprising an amyloid ⁇ -specific binding substance that is labeled with a nucleic acid fragment and specifically binds to amyloid ⁇ .
- the kit according to [9] further comprising a substance that detects biomarkers present on the surface of exosomes derived from brain neurons.
- a substance that detects a biomarker present on the surface of exosomes derived from the brain nerve cell is a substance that specifically binds to a biomarker present on the surface of exosomes derived from the brain nerve cell, according to [10] kit.
- kit for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood, which is labeled with a nucleic acid fragment and specifically binds to a biomarker present on the surface of the brain nerve cell-derived exosomes a kit comprising an exosome surface biomarker-specific binding agent and an amyloid- ⁇ -specific binding agent that specifically binds to amyloid- ⁇ .
- the biomarker is ganglioside GM1.
- a method for evaluating the accumulation level of amyloid ⁇ in the brain comprising a step of detecting amyloid ⁇ bound to exosomes derived from brain neurons in the blood, and the amount of amyloid ⁇ detected, the amyloid in the brain and a step of evaluating the ⁇ accumulation level.
- Detection of amyloid ⁇ bound to exosomes derived from brain neurons is performed by the detection method according to any one of [1] to [8], [15] evaluation method.
- the present invention it is possible to provide a technique for rapidly and highly sensitively detecting amyloid ⁇ bound to exosomes derived from brain neurons and a technique for evaluating the accumulation level of amyloid ⁇ in the brain.
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 1 is a schematic cross-sectional view showing an example of a fluidic device
- FIG. 10 is a diagram showing a fluorescence image in Experimental Example 1; 4 is a graph showing fluorescence intensity in Experimental Example 1.
- FIG. The left figure shows the linear scale fluorescence intensity, and the right figure shows the log scale fluorescence intensity.
- 2 is a graph showing the fluorescence intensity of exosomes of 3-week-old or 13-week-old human familial mutant APP gene-introduced mice in Experimental Example 2.
- FIG. 10 is a diagram showing a fluorescence image in Experimental Example 1; 4 is a graph showing fluorescence intensity in Experimental Example 1.
- FIG. The left figure shows the linear scale fluorescence intensity, and the right figure shows the log scale fluorescence intensity.
- 2 is a graph showing the fluorescence intensity of exosomes of 3-week-old or 13-week-old human familial mutant APP gene-introduced mice in Experimental Example 2.
- Control indicates the case of using a buffer solution (PBS) instead of exosomes.
- 10 is a graph showing concentrations of amyloid ⁇ 40 (A ⁇ 40) and amyloid ⁇ 42 (A ⁇ 42) in the brain tissue of human familial mutant APP gene-introduced mouse in Experimental Example 3.
- FIG. The left figure shows the concentration of amyloid ⁇ 40, and the right figure shows the concentration of amyloid ⁇ 42.
- FIG. 10 shows immunohistochemical staining of amyloid ⁇ in brain tissues of 3-week-old or 13-week-old human familial mutant APP gene-introduced mice in Experimental Example 3.
- the left figure is immunohistochemical staining of amyloid ⁇ in the brain tissue of 3-week-old human familial mutant APP gene-transduced mouse, and the right figure is amyloid ⁇ in 13-week-old human familial mutant APP gene-transduced mouse brain tissue. Immunohistochemical staining is shown.
- 4 is a graph showing the concentration of free amyloid ⁇ 40 (A ⁇ 40) or amyloid ⁇ 42 (A ⁇ 42) in the serum of 3-week-old or 13-week-old human familial mutant APP gene-introduced mice in Comparative Example 1.
- FIG. The left figure shows the concentration of amyloid ⁇ 40
- the right figure shows the concentration of amyloid ⁇ 42.
- the present invention is a method for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood, wherein the amyloid ⁇ bound to exosomes derived from brain neurons in blood is labeled with a nucleic acid fragment. Also provided is a detection method comprising the steps of binding an amyloid ⁇ -specific binding substance that specifically binds to amyloid ⁇ , and detecting the amyloid ⁇ -specific binding substance. The detection method according to this embodiment will be described below.
- FIG. 1 is a schematic diagram for explaining the detection method of this embodiment.
- the detection method of the present embodiment first, amyloid ⁇ 111 bound to exosomes 110 derived from brain neurons in blood, and labeled with a nucleic acid fragment 121, amyloid that specifically binds to amyloid ⁇ 111 ⁇ -specific binding substance 120 is bound.
- Amyloid ⁇ 111 binds to biomarkers 112 present on the surface of exosomes 110 derived from brain neurons.
- Blood includes whole blood, serum, plasma and the like.
- Exosomes are membrane vesicles with a diameter of about 40 nm to 150 nm that are secreted by most cells. In vivo, it is observed in body fluids such as saliva, blood, urine, amniotic fluid, and malignant ascites, and is also secreted from cultured cells. In recent years, it has been pointed out that exosomes may play a role in transmitting information to distant cells and tissues. Exosomes contain various proteins, lipids, and nucleic acids, and are thought to cause functional and physiological changes when transported to different cells. Specific examples thereof have been suggested to play roles in mediating adaptive immune responses against infectious pathogens and tumors, tissue repair, neurotransmission, transport of pathogenic proteins, and the like.
- exosomes are exosomes derived from brain neurons.
- Amyloid ⁇ which is considered to be a causative factor of Alzheimer's disease, is known to bind to exosomes derived from brain neurons, be transported, accumulate in the brains of Alzheimer's disease patients, and form plaques. Therefore, by using a substance that specifically binds to amyloid ⁇ bound to exosomes derived from brain neurons, it is possible to detect amyloid ⁇ bound to exosomes derived from brain neurons.
- Amyloid ⁇ 111 is bound to exosomes 110 by binding to biomarkers 112 present on the membrane surface of exosomes 110 derived from brain neurons. Examples of biomarkers 112 present on the membrane surface of exosomes 110 derived from brain neurons and capable of binding to amyloid ⁇ 111 include ganglioside GM1 and the like.
- the amyloid ⁇ -specific binding substance 120 labeled with the nucleic acid fragment 121 bound to the amyloid ⁇ 111 bound to the exosomes 110 derived from brain neurons is detected.
- the detection method of this embodiment is suitable for detection by digital measurement.
- FIG. 2 is a schematic cross-sectional view showing an example of a fluidic device.
- the fluidic device 200 includes a substrate 210 and a lid member 220 arranged to face the substrate 210 .
- the lid member 220 has a convex portion 221 and the tip of the convex portion 221 is in contact with the substrate 210 .
- well array 240 is integrally molded with substrate 210 on one surface of substrate 210 and faces lid member 220 .
- Well array 240 has a plurality of wells 241 .
- the lid member 220 may be welded or adhered to the substrate 210 .
- the well 241 is open on the surface of the substrate 210. Although the shape, size, and arrangement of the wells 241 are not particularly limited, it is preferable to introduce exosomes derived from one brain nerve cell into one well 241 .
- Well 241 is preferably a microwell with a small volume. For example, the volume of one well 241 may be on the order of 10 fL to 100 pL.
- a plurality of wells 241 of the same shape and size form a well array 240 .
- the same shape and same size means that they have the same shape and the same capacity to the extent required for performing digital measurement, and variations to the extent of manufacturing error are allowed.
- the diameter of the well 241 may be, for example, about 1 to 10 ⁇ m, and the depth of the well 241 may be, for example, about 1 to 10 ⁇ m.
- the arrangement of the wells 241 is not particularly limited, and may be arranged in a triangular lattice, may be arranged in a square lattice, or may be arranged at random.
- a space is formed between the well array 240 and the lid member 220 due to the presence of the protrusions 221 .
- the space constitutes the channel 230 .
- the channel 230 functions as a path for feeding a liquid in which exosomes derived from brain nerve cells, amyloid ⁇ -specific binding substances labeled with nucleic acid fragments, and the like are dispersed, and a sealing liquid described later.
- the shape, structure, capacity, etc. of the channel 230 are not particularly limited, but the height of the channel 230 (the distance between the surface of the substrate 210 and the surface of the lid member 220 facing the substrate 210) is, for example, 500 ⁇ m or less. For example, it may be 300 ⁇ m or less, for example, it may be 200 ⁇ m or less, or it may be, for example, 100 ⁇ m or less.
- the convex portion 221 may be formed integrally with the lid member 220 .
- the lid member 220 can be molded into a plate-like shape having the protrusions 221 by molding a thermoplastic resin fluid using a molding die, for example.
- the lid member 220 may be formed with a reagent introduction port 222 and a reagent discharge port 223 .
- the lid member 220 When the lid member 220 has the protrusions 221, the lid member 220 and the substrate 210 are overlapped so that the protrusions 221 are in contact with the surface of the substrate 210 on which the wells 241 are opened. As a result, the space between the lid member 220 and the substrate 210 becomes the channel 230 .
- the lid member 220 and the substrate 210 may be welded by laser welding or the like.
- FIG. 5 is a schematic cross-sectional view showing an example of a fluidic device.
- fluidic device 500 includes substrate 210 and wall member 510 .
- well array 240 is formed integrally with substrate 210 on one surface of substrate 210 .
- Well array 240 has a plurality of wells 241 .
- the fluidic device 500 mainly differs from the above-described fluidic device 200 in that it does not have a lid member 220 . Therefore, fluidic device 500 does not have a flow channel.
- the lid member 220 and the convex portion 221 are integrally formed.
- the lid member 220 and the projection 221 may be formed separately.
- the well array 240 is formed integrally with the substrate 210 on one surface of the substrate 210 .
- the well array does not have to be integrally molded with substrate 210 .
- a well array 240 molded separately from the fluidic device may be placed on the substrate 210 of the fluidic device.
- a resin layer may be laminated on the surface of the substrate 210 and a well array may be formed in the resin layer by etching or the like.
- the substrate 210 is formed using resin, for example.
- resin for example.
- the type of resin is not particularly limited, it is preferably a resin that is resistant to reagents and sealing liquids.
- the signal to be detected is fluorescence, it is preferable to use a resin with little autofluorescence. Examples include, but are not limited to, cycloolefin polymers, cycloolefin copolymers, silicon, polypropylene, polycarbonate, polystyrene, polyethylene, polyvinyl acetate, fluororesins, and amorphous fluororesins.
- a plurality of wells 241 may be formed on one surface of the substrate 210 in the plate thickness direction.
- Methods of forming wells using a resin include injection molding, thermal imprinting, optical imprinting, and the like.
- a well array may be formed by laminating a fluororesin on the substrate 210 and processing the fluororesin by etching or the like.
- a fluorine resin for example, CYTOP (registered trademark) (Asahi Glass) or the like can be used.
- the material of the lid member 220 is preferably a resin with low autofluorescence, and may be, for example, a thermoplastic resin such as cycloolefin polymer or cycloolefin copolymer.
- the lid member 220 may be made of a material that does not transmit light having a wavelength in the vicinity of the wavelength detected during fluorescence observation of the signal, or may be made of a material that completely does not transmit light.
- the lid member 220 may be made of thermoplastic resin to which carbon, metal particles, or the like is added.
- the detection method of the present embodiment is a method for detecting amyloid ⁇ 111 bound to exosomes 110 derived from brain neurons in blood, wherein the exosomes 110 derived from brain neurons in blood are labeled with a nucleic acid fragment 121, amyloid ⁇ and a step of detecting the amyloid ⁇ -specific binding substance 120. According to the method of this embodiment, amyloid ⁇ 111 bound to exosomes 110 derived from brain neurons can be detected.
- the detection method of the present embodiment may further comprise a step of detecting biomarkers 112 present on the surface of exosomes 110 derived from brain neurons.
- the step of detecting biomarkers 112 present on the surface of brain nerve cell-derived exosomes 110 uses a substance that detects biomarkers 112 present on the surface of brain nerve cell-derived exosomes 110, exosomes 110 derived from brain nerve cells.
- biomarkers 112 by detecting biomarkers 112 present on the surface of the If biomarkers 112 are present on the surface of exosomes 110 derived from brain neurons, a substance that specifically binds to biomarkers 112 present on the surface of exosomes 110 derived from brain neurons (exosome surface biomarker-specific binding substance) Since it is possible to capture brain nerve cell-derived exosomes 110 using, the detection of biomarkers 112 present on the surface of brain nerve cell-derived exosomes 110 is performed using a biomarker-specific binding substance on the exosome surface, cranial nerves This can be done by capturing exosomes 110 derived from cells.
- the reagent liquid L210 is introduced from the introduction port 222 of the fluidic device 200 and sent to the channel 230.
- Reagent solution L210 is a liquid in which amyloid ⁇ -specific binding substance 120 labeled with brain nerve cell-derived exosomes 110 and nucleic acid fragment 121 is dispersed, and also contains a reagent for detecting nucleic acid fragment 121.
- amyloid ⁇ 111 is bound to exosomes 110 derived from brain neurons
- amyloid ⁇ -specific binding substance 120 labeled with nucleic acid fragment 121 binds to amyloid ⁇ 111 bound to exosomes 110 derived from brain neurons. .
- the reagent liquid L210 sent to the channel 230 contacts the well array 240.
- a reagent solution L210 is accommodated inside the well 241 .
- brain nerve cell-derived exosomes 110, amyloid ⁇ -specific binding substance 120 labeled with nucleic acid fragment 121, and a reagent for detecting nucleic acid fragment 121 are introduced into well 241.
- the number of brain nerve cell-derived exosomes 110 to be introduced into one well 241 is not particularly limited, but preferably one or less, i.e., 0 or 1 brain nerve cell-derived exosomes 110 are introduced into one well 241. be done.
- amyloid ⁇ 111 bound to exosomes 110 derived from brain nerve cells can be detected in units of one, that is, digital measurement becomes possible.
- the means for introducing the brain nerve cell-derived exosomes 110 into the well 241 is not particularly limited, and an appropriate means can be selected according to the selected brain nerve cell-derived exosomes 110.
- exosomes 110 derived from brain nerve cells are sedimented in the fluidic device (within the channel) by their own weight, and a method of distributing them to the wells 241 can be mentioned.
- exosomes 110 derived from brain neurons using the above-mentioned exosome surface biomarker-specific binding substance, exosomes surface biomarker-specific binding substance to exosomes 110 derived from brain neurons that are difficult to sediment under their own weight may be bound and sent, in advance in the well 241, by immobilizing the biomarker-specific binding substance on the exosome surface and capturing the exosomes 110 derived from the sent brain nerve cells, brain nerve cells It is also possible to improve the efficiency of introduction of exosomes 110 derived from wells 241.
- the step of binding biomarker-specific binding substances on the surface of exosomes to biomarkers 112 present on the surface of brain nerve cell-derived exosomes 110 to capture brain nerve cell-derived exosomes 110 is any of the detection methods of the present embodiment. can be done at the time of For example, in this step, prior to the step of introducing brain nerve cell-derived exosomes 110 into the well 241, the brain nerve cell-derived exosomes 110 and the exosome surface biomarker-specific binding substance are brought into contact in the sample tube. good too.
- the exosomes 110 derived from brain neurons are introduced into the well 241, and within the well 241 the biomarker-specific binding substance on the exosome surface and the brain nerve cell-derived Exosomes 110 may be contacted.
- the exosome surface biomarker-specific binding substance may be a conjugate between a solid phase and an exosome surface biomarker-specific binding substance.
- Solid phases include particles, films, substrates, and the like.
- the exosome surface biomarker-specific binding substance may be one type, or may be two or more types. For example, there may be three types, four types, or five or more types.
- the particles are not particularly limited, and include polymer particles, magnetic particles, glass particles, and the like. Particles are preferably surface-treated particles to avoid non-specific adsorption. Particles having a functional group such as a carboxyl group on the surface are preferred for immobilizing a specific binding substance. More specifically, JSR's product name "Magnosphere LC300" or the like can be used.
- Amyloid ⁇ -specific binding substances 120 and exosome surface biomarker-specific binding substances include antibodies, antibody fragments, aptamers, and the like.
- antibody fragments include Fab, F(ab') 2 , Fab', single-chain antibodies (scFv), disulfide-stabilized antibodies (dsFv), dimerized V region fragments (diabody), peptides containing CDRs, and the like. be done.
- Antibodies may be monoclonal antibodies or polyclonal antibodies. Alternatively, it may be a commercially available antibody.
- ganglioside GM1 is present as a biomarker on the surface of exosomes derived from brain neurons, so the biomarker-specific binding substance on the exosome surface is specific to ganglioside GM1. It may be an antibody, antibody fragment, aptamer, protein, etc. that specifically binds. Proteins that specifically bind to ganglioside GM1 include cholera toxin subunit B (hereinafter also referred to as CTB).
- CTB cholera toxin subunit B
- Methods for labeling amyloid ⁇ -specific binding substances with nucleic acid fragments include methods using a cross-linking agent.
- the nucleic acid fragment may be labeled with an amyloid- ⁇ specific binding substance via a linker molecule.
- the linker is not particularly limited, and examples thereof include polyethylene chains, hydrocarbon chains, peptides and the like.
- a nucleic acid fragment may be DNA or RNA. It may also contain artificial nucleic acids such as BNA and LNA.
- nucleic acid detection reaction takes about 1 minute to 30 minutes, enabling rapid nucleic acid detection.
- the method of immobilizing the biomarker-specific binding substance on the exosome surface on the particle surface is not particularly limited, and the method by physical adsorption, the method by chemical binding, the method of using avidin-biotin binding, protein G or protein A. and a method that utilizes the binding of an antibody.
- the method by physical adsorption includes a method of immobilizing a biomarker-specific binding substance on the exosome surface on the particle surface by hydrophobic interaction and electrostatic interaction.
- Methods using chemical bonding include a method using a cross-linking agent.
- the carboxyl group of the biomarker-specific binding substance on the exosome surface is reacted with a cross-linking agent to form an active ester, and then the hydroxyl group and the ester group are reacted to exosomes.
- Surface biomarker-specific binding substances can be immobilized on the particle surface.
- one exosome surface biomarker-specific binding substance has exosomes 110 derived from brain nerve cells. It is preferable to form a conjugate between the biomarker-specific binding substance on the exosome surface and exosomes 110 derived from brain nerve cells under conditions where 0 or 1 is detected.
- one well 241 is preferably configured to introduce 0 or 1 biomarker-specific binding substance on the surface of exosomes. This enables digital measurement.
- amyloid ⁇ 111 is bound to exosomes 110 derived from brain neurons
- Amyloid ⁇ 111 bound to exosomes 110 and amyloid ⁇ -specific binding substance 120 labeled with nucleic acid fragment 121 bind to form complex 100 .
- Formation of the complex 100 may be performed within the sample tube or within the well 241 .
- ⁇ Enclosure process After introducing exosomes 110 derived from brain nerve cells, amyloid ⁇ -specific binding substance 120 or the like labeled with nucleic acid fragment 121 into well 241, a step of sealing the opening of well 241 may be performed.
- the method of sealing the opening of the well 241 is not particularly limited as long as the liquid contained in one well 241 and the liquid contained in another well 241 do not mix with each other.
- the well 241 may be sealed by covering the opening of the well 241 with a sealing liquid.
- the opening of the well 241 may be sealed by laminating a plate-like member such as a glass plate.
- the sealing liquid L220 is sent from the introduction port 222 of the lid member 220 to the channel 230 between the substrate 210 and the lid member 220.
- the sealing liquid L220 sent to the channel 230 contacts the well array 240.
- the sealing liquid L220 pushes away and replaces the reagent liquid L210 not contained in the well 241 among the reagent liquid L210 sent to the channel 230 .
- the sealing liquid L220 individually seals the plurality of wells 241 containing the reagent liquid L210 containing exosomes 110 derived from brain neurons, and the wells 241 become independent reaction spaces (micropartitions 242).
- FIG. 4 shows a state in which all wells 241 of well array 240 are sealed with sealing liquid L220 to form sealed wells (microcompartments) 242 .
- Lipids forming a lipid bilayer membrane include, for example, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), Examples thereof include, but are not limited to, mixtures thereof.
- DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
- DOPG 1,2-dioleoyl-sn-glycero-3-phosphoglycerol
- Wells 242 sealed by any of the sealing methods described above may contain amyloid ⁇ -specific binding substance 120 that does not bind to exosomes 110 derived from brain neurons.
- the sealing liquid is a liquid capable of individually sealing the liquids introduced into the plurality of wells 241 so as not to mix with each other to form droplets (microdroplets), and is preferably an oily solution. , more preferably oil.
- oil fluorine-based oil, silicone-based oil, hydrocarbon-based oil, or a mixture thereof can be used. More specifically, the product name "FC-40” manufactured by Sigma can be used. FC-40 (CAS number: 86508-42-1) is a fluorinated aliphatic compound with a specific gravity of 1.85 g/mL at 25°C.
- Detection of the nucleic acid fragment 121 is preferably performed using a signal amplification reaction.
- Signal amplification reactions include, for example, Invasive Cleavage Assay (ICA).
- the ICA reaction is related to the principle that signal amplification proceeds through a cycle of two reactions: (1) complementary binding between nucleic acids and (2) recognition and cleavage of the triplex structure by an enzyme.
- the ICA reaction is less affected by reaction cycle inhibition by contaminants. Therefore, by using the ICA reaction, exosomes 110 derived from brain neurons can be detected with high accuracy.
- the reagent solution L210 liquid containing the brain nerve cell-derived exosomes 110 and the amyloid ⁇ -specific binding substance 120 contains reaction reagents necessary for the ICA reaction.
- Reaction reagents required for the ICA reaction include ICA reaction reagents such as flap probes, invasion probes, flap endonuclease (FEN), and fluorescent substrates. Flap probes and invasion probes are nucleic acid fragments designed to hybridize to nucleic acid fragment 121 and form a flap structure with nucleic acid fragment 121 .
- FIG. 8 is a schematic diagram explaining an example of the ICA method.
- the flap probe and the invasion probe are hybridized to the nucleic acid fragment 121 .
- flap probe 810 and invasion probe 130 hybridize to nucleic acid fragment 121 .
- a first flap portion 811 is formed.
- the first flap site 811 is reacted with FEN, the first flap site 811 is cleaved and a nucleic acid fragment 811 is generated. Nucleic acid fragment 811 then hybridizes to a fluorescent substrate (nucleic acid fragment 820 ) to form second flap region 821 .
- a fluorescent substance F is bound to the 5' end of the nucleic acid fragment 820, and a quenching substance Q is bound several bases 3' from the 5' end of the nucleic acid fragment 820.
- the second flap site 821 is reacted with FEN, the second flap site 821 is cleaved and a nucleic acid fragment 821 is produced.
- the fluorophore F is separated from the quencher Q, generating a fluorescence signal.
- the nucleic acid fragment 121 can be detected by detecting this fluorescence signal.
- the reagent liquid L210 a common liquid used in biochemical analysis performed using a fluidic device can be used, preferably an aqueous solution. Further, the reagent liquid L210 may contain a surfactant or the like to make it easier to enclose the liquid in the well.
- the fluorescent substance F is liberated from the quenching substance Q by an isothermal enzymatic reaction, and a predetermined fluorescent signal is generated in response to the excitation light. emitted.
- a known appropriate method can be selected according to the type of signal to be detected. For example, when observing a fluorescent signal, the well 242 is irradiated with excitation light corresponding to the fluorescent substance, and fluorescence emitted by the fluorescent substance is observed. For example, as shown in FIG. 4, a predetermined reaction is performed in sealed well 242 and the generated signal is observed.
- Well 242R is the well in which signal was detected and well 242 is the well in which no signal was detected.
- a reagent liquid L210 is introduced into the fluidic device 500 as shown in FIG.
- Reagent solution L210 is a liquid in which brain nerve cell-derived exosomes 110 and amyloid ⁇ -specific binding substance 120 labeled with nucleic acid fragment 121 are dispersed, and also contains a reagent for detecting nucleic acid fragment 121.
- the concentration of the brain nerve cell-derived exosomes 110 is preferably adjusted so that one molecule or less of the brain nerve cell-derived exosomes 110 enters the wells 241 per well.
- a sealing liquid L220 is introduced into the fluidic device 500.
- the specific gravity of the sealing liquid L220 is greater than that of the reagent liquid L210. Therefore, the sealing liquid L220 sinks below the reagent liquid L210 that is not contained in the wells 241 among the reagent liquids L210 and contacts the well array 240 . Then, the sealing liquid L220 individually seals the plurality of wells 241 containing the reagent liquid L210 containing brain nerve cell-derived exosomes to form independent reaction spaces (micropartitions 242).
- Well 242R is the well in which signal was detected and well 242 is the well in which no signal was detected.
- the present invention in one embodiment, is a method for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood, wherein the exosome surface labeled with a biomarker present on the exosome surface and a nucleic acid fragment
- a step of binding a substance that specifically binds to a biomarker present on the exosome surface (biomarker-specific binding substance on the exosome surface) and a step of detecting amyloid ⁇ bound to exosomes derived from brain neurons in the blood
- a detection method comprising detecting a biomarker-specific binding substance on the surface of exosomes.
- the detection method according to this embodiment will be described below.
- FIG. 9 is a schematic diagram for explaining the detection method of this embodiment.
- biomarkers 112 present on the surface of brain nerve cell-derived exosomes, labeled with a nucleic acid fragment 151, brain nerve cell-derived exosomes present on the surface and a biomarker-specific binding substance 150 on the exosome surface that specifically binds to the biomarker 112 .
- Amyloid ⁇ 111 binds to biomarkers 112 present on the surface of exosomes 110 derived from brain neurons.
- the exosome surface biomarker-specific binding agent 150 binds to the exosome-specific biomarker 112 to which amyloid ⁇ 111 is not bound.
- biomarkers 112 present on the membrane surface of exosomes 110 derived from brain neurons and capable of binding to amyloid ⁇ 111 include those described above.
- the detection method of this embodiment is suitable for detection by digital measurement.
- the detection method of this embodiment is performed by digital measurement, it is preferable to use a fluidic device having a well array in which a plurality of wells are arranged.
- the fluidic device the fluidic device described in the first embodiment is used.
- a nucleic acid fragment-labeled exosome surface biomarker-specific binding agent is used instead of a nucleic acid fragment-labeled amyloid ⁇ -specific binding agent.
- amyloid ⁇ 111 bound to biomarker 112 present on the surface of exosomes derived from brain neurons is detected.
- the step of detecting amyloid ⁇ 111 bound to the biomarker 112 present on the surface of exosomes derived from brain neurons uses an amyloid ⁇ -specific binding substance 120 that specifically binds to amyloid ⁇ , to exosomes 110 derived from brain neurons This can be done by detecting bound amyloid ⁇ 111. If amyloid ⁇ 111 is bound to the biomarker 112 present on the surface of brain nerve cell-derived exosomes, the amyloid ⁇ -specific binding substance 120 can be used to capture the brain nerve cell-derived exosomes 110. Therefore, the brain nerve cell Detection of amyloid ⁇ bound to the derived exosomes 110 can be performed by capturing the exosomes 110 derived from brain neurons using the amyloid ⁇ -specific binding substance 120.
- the reagent liquid L210 is introduced from the introduction port 222 of the fluidic device 200 and sent to the channel 230.
- Reagent solution L210 is labeled with brain nerve cell-derived exosomes 110 and nucleic acid fragments 151, is a liquid in which biomarker-specific binding substances 150 on the exosome surface are dispersed, and also contains reagents for detecting nucleic acid fragments 151.
- exosome surface biomarker-specific binding substance 150 is not bound by amyloid ⁇ 111, biomarkers 112 on the surface of exosomes 110 derived from brain neurons bind to
- the reagent liquid L210 sent to the channel 230 contacts the well array 240.
- a reagent solution L210 is accommodated inside the well 241 .
- the number of brain nerve cell-derived exosomes 110 to be introduced into one well 241 is not particularly limited, but preferably one or less, i.e., 0 or 1 brain nerve cell-derived exosomes 110 are introduced into one well 241. be done.
- amyloid ⁇ 111 bound to exosomes 110 derived from brain nerve cells can be detected in units of one, that is, digital measurement becomes possible.
- the means for introducing the brain nerve cell-derived exosomes 110 into the well 241 is not particularly limited, and an appropriate means can be selected according to the selected brain nerve cell-derived exosomes 110.
- exosomes 110 derived from brain nerve cells are sedimented in the fluidic device (within the channel) by their own weight, and a method of distributing them to the wells 241 can be mentioned.
- the amyloid ⁇ -specific binding substance 120 which can capture brain nerve cell-derived exosomes 110, the amyloid ⁇ -specific binding substance 120 is bound to the brain nerve cell-derived exosomes 110 that are difficult to sediment under their own weight.
- the liquid may be sent, and the amyloid ⁇ -specific binding substance 120 is immobilized in the well 241 in advance, and the exosomes 110 derived from the brain nerve cells are captured by the sent brain nerve cell-derived exosomes 110. 241 can also be improved.
- the step of binding amyloid ⁇ -specific binding substance 120 to amyloid ⁇ 111 bound to brain nerve cell-derived exosomes 110 and capturing brain nerve cell-derived exosomes 110 can be performed at any time in the detection method of this embodiment. can. For example, this step may be performed by contacting brain nerve cell-derived exosomes 110 and amyloid ⁇ binding substance 120 in a sample tube before the step of introducing brain nerve cell-derived exosomes 110 into the well 241. Alternatively, after introducing amyloid ⁇ -specific binding substance 120 into well 241, brain nerve cell-derived exosomes 110 are introduced into well 241, and amyloid ⁇ -specific binding substance 120 and brain nerve cell-derived exosomes 110 are introduced into well 241. may be brought into contact.
- the amyloid ⁇ -specific binding substance may be a conjugate between a solid phase and an amyloid ⁇ -specific binding substance.
- the solid phase the amyloid ⁇ -specific binding substance, and the exosome surface biomarker-specific binding substance, the same ones as described in the first embodiment are used.
- Methods for labeling biomarker-specific binding substances on the surface of exosomes with nucleic acid fragments include methods using cross-linking agents.
- the nucleic acid fragment may be labeled with an amyloid- ⁇ specific binding substance via a linker molecule.
- the linker is not particularly limited, and examples thereof include polyethylene chains, hydrocarbon chains, peptides and the like.
- a nucleic acid fragment may be DNA or RNA. It may also contain artificial nucleic acids such as BNA and LNA.
- nucleic acid detection reaction takes about 1 minute to 30 minutes, enabling rapid nucleic acid detection.
- the method for immobilizing the amyloid ⁇ -specific binding substance on the particle surface is not particularly limited, and includes a method using physical adsorption, a method using chemical bonding, a method using avidin-biotin binding, and a method using protein G or protein A and an antibody.
- a method using the combination of The physical adsorption method includes a method in which the amyloid ⁇ -specific binding substance is immobilized on the particle surface by hydrophobic interaction or electrostatic interaction.
- Methods using chemical bonding include a method using a cross-linking agent.
- the carboxyl group of the amyloid ⁇ -specific binding substance is reacted with a cross-linking agent to form an active ester, and then the hydroxyl group is reacted with the ester group to obtain amyloid ⁇ -specific A binding substance can be immobilized on the particle surface.
- one well 241 is preferably configured to introduce 0 or 1 amyloid ⁇ -specific binding substance. This enables digital measurement.
- amyloid ⁇ 111 When amyloid ⁇ 111 is bound to brain nerve cell-derived exosomes 110, the amyloid ⁇ 111 bound to the brain nerve cell-derived exosomes 110 and the amyloid ⁇ -specific binding substance 120 are bound and introduced into the well 241.
- the brain nerve cell-derived exosomes 110, labeled with nucleic acid fragment 151, exosome surface biomarker-specific binding substance 150 is brought into contact, the brain nerve cell-derived exosomes 110, labeled with nucleic acid fragment 151 , binds to a biomarker-specific binding substance 150 on the exosome surface to form a complex 100. Formation of the complex 100 may be performed within the sample tube or within the well 241 .
- the encapsulation step after introducing exosomes 110 derived from brain nerve cells, nucleic acid fragment 151-labeled exosome surface biomarker-specific binding substance 150, etc. into well 241 can be performed in the same manner as in the first embodiment. can.
- nucleic acid fragment 151 is detected. Detection of the nucleic acid fragment 151 can be performed in the same manner as in the first embodiment except that the nucleic acid fragment 151 is used instead of the nucleic acid fragment 121 .
- a reagent liquid L210 is introduced into the fluidic device 500 as shown in FIG.
- Reagent solution L210 is a liquid in which exosomes 110 derived from brain nerve cells and biomarker-specific binding substances 150 on the surface of exosomes labeled with nucleic acid fragments 151 are dispersed, and also contains reagents for detecting nucleic acid fragments 151.
- the concentration of the brain nerve cell-derived exosomes 110 is preferably adjusted so that one molecule or less of the brain nerve cell-derived exosomes 110 enters the wells 241 per well.
- a sealing liquid L220 is introduced into the fluidic device 500.
- the specific gravity of the sealing liquid L220 is greater than that of the reagent liquid L210. Therefore, the sealing liquid L220 sinks below the reagent liquid L210 that is not contained in the wells 241 among the reagent liquids L210 and contacts the well array 240 . Then, the sealing liquid L220 individually seals the plurality of wells 241 containing the reagent liquid L210 containing brain nerve cell-derived exosomes to form independent reaction spaces (micropartitions 242).
- Well 242R is the well in which signal was detected and well 242 is the well in which no signal was detected.
- the present invention provides a kit for detecting amyloid ⁇ 111 bound to brain nerve cell-derived exosomes 110 in blood, which is labeled with a nucleic acid fragment 121 and contains an amyloid ⁇ specific binding substance 120, Offer a kit.
- the kit of this embodiment includes amyloid ⁇ 111 bound to exosomes 110 derived from brain neurons in blood, and an amyloid ⁇ -specific binding substance 120 that specifically binds to amyloid ⁇ labeled with a nucleic acid fragment 121, and a step of detecting the amyloid ⁇ -specific binding substance 120. can.
- exosomes derived from brain neurons, amyloid ⁇ -specific binding substances, and nucleic acid fragments are the same as those described above.
- the kit of this embodiment may include a well array 240 having multiple wells 241 .
- the kit of this embodiment may further include a sealing liquid L220 for sealing the opening of the well 241.
- FIG. The sealing liquid L220 is the same as described above.
- kit of the present embodiment may further contain a substance that detects biomarkers 112 present on the surface of exosomes 110 derived from brain neurons.
- a substance that detects biomarkers 112 present on the surface of exosomes 110 derived from brain neurons include the above-described exosome surface biomarker-specific binding substances.
- kit of this embodiment may further contain a reagent for detecting the nucleic acid fragment 121.
- reagents examples include the reagents for the ICA reaction described above, and specific examples include flap probes, invasion probes, flap endonucleases (FEN), fluorescent substrates, and the like.
- the present invention provides a kit for detecting amyloid ⁇ bound to exosomes derived from brain neurons in blood, wherein the biomarkers present on the surface of the brain nerve cell-derived exosomes labeled with a nucleic acid fragment
- a kit is provided that includes an exosome surface biomarker-specific binding agent that specifically binds to and an amyloid- ⁇ -specific binding agent that specifically binds to amyloid- ⁇ .
- the kit of this embodiment is a method for detecting amyloid ⁇ 111 bound to exosomes 110 derived from brain nerve cells in blood, and is labeled with a biomarker 112 present on the surface of the exosomes 110 and a nucleic acid fragment 151.
- the step of binding the exosome surface biomarker-specific binding substance 150, exosomes 110 derived from brain neurons in the blood amyloid bound can also be said to be for use in a detection method comprising the step of detecting ⁇ 111 and the step of detecting the biomarker-specific binding substance 150 on the exosome surface.
- the exosomes derived from brain neurons, the amyloid ⁇ -specific binding substance, the exosome surface biomarker-specific binding substance, and the nucleic acid fragment are the same as those described above.
- the kit of this embodiment may include a well array 240 having multiple wells 241 .
- the kit of this embodiment may further include a sealing liquid L220 for sealing the opening of the well 241.
- FIG. The sealing liquid L220 is the same as described above.
- kit of this embodiment may further contain a reagent for detecting the nucleic acid fragment 151.
- reagents examples include the reagents for the ICA reaction described above, and specific examples include flap probes, invasion probes, flap endonucleases (FEN), fluorescent substrates, and the like.
- the present invention is a method for evaluating the accumulation level of amyloid ⁇ in the brain, comprising the steps of detecting amyloid ⁇ bound to exosomes derived from brain nerve cells in blood, and detecting the amount of amyloid ⁇ and Evaluating the level of amyloid ⁇ accumulation in the brain.
- the evaluation method of this embodiment when the detected amount of amyloid ⁇ bound to exosomes derived from brain neurons is high, it can be evaluated that the accumulation level of amyloid ⁇ in the brain is high. In addition, when the detected amount of amyloid ⁇ bound to exosomes derived from brain neurons is low, it can be evaluated that the accumulation level of amyloid ⁇ in the brain is low.
- the evaluation method of this embodiment can evaluate the level of amyloid ⁇ accumulation in the brain, early treatment and prevention of Alzheimer's disease, which is thought to be caused by amyloid ⁇ accumulation in the brain, becomes possible. For example, when the evaluation method of this embodiment determines that the amyloid ⁇ accumulation level in the brain is high, it becomes possible to start treatment for Alzheimer's disease.
- the detection of amyloid ⁇ bound to exosomes derived from brain neurons in blood can be performed using the above-described detection method for amyloid ⁇ bound to exosomes derived from brain neurons in blood. Therefore, the evaluation method of this embodiment can quickly and accurately evaluate the accumulation level of amyloid ⁇ in the brain.
- the evaluation method of the present embodiment can evaluate the accumulation level of amyloid ⁇ in the brain only by collecting blood from a subject, is not invasive like a cerebrospinal fluid test, and is also a PET imaging method. No special equipment is required.
- Example 1 ⁇ Reagent preparation> (Exosome-containing sample derived from brain nerve cells)
- a sample containing brain neuron-derived exosomes bound to amyloid ⁇ is a mouse neuro 2A (N2a) cell containing human amyloid ⁇ precursor protein (amyloid- ⁇ precursor protein; hereinafter also referred to as APP) isoform 751 (APP751).
- the culture supernatant is stepwise centrifuged at 2000 x g for 10 minutes, 10000 x g for 30 minutes, and 100000 x g for 70 minutes to collect exosomes, and samples containing exosomes derived from brain neurons. and Collection of exosomes from serum was performed using MagCapture (registered trademark) exosome isolation kit PS (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.).
- MagCapture registered trademark
- exosome isolation kit PS manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
- CTB-immobilized magnetic beads In order to immobilize Cholera Toxin subunit B (CTB, manufactured by Sigma) on magnetic beads, CTB was added to a solution of carboxyl group-modified magnetic beads (Magnosphere, LC300, manufactured by JSR) and mixed to 100 ⁇ L. Then, the mixture was reacted for 30 minutes with a rotator, and the condensing agent EDC was added and reacted for 3 hours to immobilize CTB on carboxyl magnetic beads.
- CTB Cholera Toxin subunit B
- CTB beads Immobilized carboxyl magnetic beads
- DNA fragment 1 has the base sequence shown in SEQ ID NO:1.
- Flap probe 1 having the nucleotide sequence shown in SEQ ID NO:2.
- - Invasion probe 1 having the nucleotide sequence shown in SEQ ID NO:3.
- DNA fragment 1 having the nucleotide sequence shown in SEQ ID NO: 1 was bound to an anti-amyloid ⁇ monoclonal antibody (model "BAN50", manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) to prepare a nucleic acid-labeled anti-amyloid ⁇ antibody.
- a commercially available kit (trade name “Protein-Oligo Conjugation Kit” manufactured by Sollink) was used for conjugation of DNA fragments.
- the nucleic acid-labeled anti-amyloid ⁇ antibody was prepared so that the amount of nucleic acid modified was 5 to 20 times that of the antibody (one antibody molecule).
- An ICA reaction reagent was prepared as a nucleic acid detection reagent in order to detect a nucleic acid-modified antibody by the ICA reaction.
- the reagent composition of the ICA reaction reagent in this experimental example is as follows.
- the ICA reaction reagents in this experimental example are 0.1 ⁇ M flap probe 1 (SEQ ID NO: 2), 1 ⁇ M invasion probe 1 (SEQ ID NO: 3), 2 ⁇ M FRET Cassette (FAM) (manufactured by Hologic), and 2 ⁇ M FRET Cassette (Redmond RED).
- CTB-immobilized magnetic beads specifically binds to ganglioside GM1 present on the membrane surface of exosomes derived from brain neurons. Therefore, exosomes derived from brain neurons can be captured using CTB-immobilized magnetic beads. Specifically, in the following manner, CTB-immobilized magnetic beads are used to capture brain nerve cell-derived exosomes, and amyloid ⁇ bound to the captured brain nerve cell-derived exosomes and an amyloid ⁇ -specific binding substance. allowed to bind and form a complex.
- PBS adjusted to contain 6 ⁇ 10 5 CTB-immobilized carboxyl magnetic beads (CTB beads), 0, 4, 20, 100, 500, 2000, 8000, or 15000 ng of exosomes in a sample tube; Nucleic acid-modified anti-amyloid ⁇ antibodies adjusted to 1 ng/mL were mixed to a total volume of 100 ⁇ L, and reacted on a rotator at room temperature for 1 hour to form a complex.
- the magnetic beads obtained were magnetically captured using a magnet stand, and the procedure of removing the supernatant and adding PBS containing 0.1% Tween (PBS-T) was repeated five times for washing. The supernatant was removed to obtain the complex.
- the resulting complex was diluted after washing to prepare each reaction mixture.
- a substrate having a large number of minute wells was made of COP (cycloolefin polymer), and a cover made of COP was attached to the substrate to make a device.
- the total well volume per cm 2 was 0.93 ⁇ L.
- the total number of wells used for counting was 1,000,000.
- ⁇ Liquid delivery of reaction mixed solution > 18 ⁇ L of each of the above reaction mixtures was sent to the device and introduced into each well. Subsequently, 200 ⁇ L of FC-40 (manufactured by Sigma) was delivered as a sealing liquid to seal each well.
- ⁇ Nucleic acid detection reaction> The above device after feeding each reaction mixture solution was set on a hot plate and reacted at 66° C. for 25 minutes. As a result, recognition of the nucleic acid fragment modifying the anti-amyloid ⁇ antibody by the flap probe and the invasion probe, cleavage of the flap probe by FEN, binding of the released flap probe fragment to the FRET Cassette, and cleavage of the FRET Cassette by FEN. progressed and a fluorescent signal was emitted from Alexa488.
- Example 2 ⁇ Reagent preparation> (Exosome-containing sample derived from brain nerve cells) As a sample containing brain nerve cell-derived exosomes, the serum of 3-month-old or 13-month-old mice [human APP Sw, Ind transgenic mice (J20, Jackson Laboratory)] into which a human familial mutant APP gene was introduced was used. Collection of exosomes from serum was performed using MagCapture (registered trademark) exosome isolation kit PS (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.). PBS was used as a control containing no exosomes.
- MagCapture registered trademark
- exosome isolation kit PS manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
- CTB-immobilized magnetic beads ⁇ Reaction of exosomes, CTB-immobilized magnetic beads and nucleic acid-modified anti-amyloid ⁇ antibody>
- CTB beads CTB-immobilized carboxyl magnetic beads
- 50, 100, 250 ⁇ L of exosomes collected from each mouse serum or PBS nucleic acid-modified anti-amyloid adjusted to 0.1 ng/mL
- the ⁇ antibody was mixed so that the total amount was 100 ⁇ L, and reacted on a rotator at room temperature for 1 hour to form a complex.
- the magnetic beads obtained were magnetically captured using a magnet stand, and the procedure of removing the supernatant and adding PBS containing 0.1% Tween (PBS-T) was repeated five times for washing. The supernatant was removed to obtain the complex. The resulting complex was washed and diluted with PBS to prepare a reaction mixture.
- PBS-T PBS containing 0.1% Tween
- ⁇ Nucleic acid detection reaction> The above device after feeding each reaction mixture solution was set on a hot plate and reacted at 66° C. for 25 minutes. As a result, recognition of the nucleic acid fragment modifying the anti-amyloid ⁇ antibody by the flap probe and the invasion probe, cleavage of the flap probe by FEN, binding of the released flap probe fragment to the FRET Cassette, and cleavage of the FRET Cassette by FEN. progressed and a fluorescent signal was emitted from Alexa488.
- Example 3 (Detection of amyloid ⁇ in mouse brain tissue)
- the brain tissue of the 3-month-old or 13-month-old human familial mutant APP gene-introduced mouse used in Experimental Example 2 was excised, the left hemisphere was separated, dissolved in 5 M guanidine hydrochloride, and then subjected to A ⁇ ELISA kit (Fujifilm Wako Pure Chemical Industries, Ltd.). Co.) was used to measure the concentrations of amyloid ⁇ 40 and amyloid ⁇ 42 in the mouse brain tissue.
- brain tissue was excised, and the right hemisphere was immersed and fixed overnight in 4% paraformaldehyde to prepare a sagittal paraffin section.
- FIG. 13 shows the results of measurement of amyloid ⁇ 40 and amyloid ⁇ 42 concentrations in mouse brain tissue
- FIG. 14 shows the results of immunohistochemical staining of amyloid ⁇ in the mouse brain tissue.
- amyloid ⁇ was not accumulated in the brain tissue of 3-month-old human familial mutant APP gene-transduced mice, but the brain tissue of 13-month-old human familial mutant APP gene-transfected mice did not accumulate. Amyloid ⁇ was accumulated in the tissue.
- amyloid ⁇ was not detected in the exosomes in the serum of 3-month-old human familial mutant APP transgenic mice in which amyloid ⁇ had not accumulated in brain tissue. It was revealed that amyloid ⁇ was detected in exosomes in the serum of 13-month-old human familial mutant APP gene-introduced mice in which amyloid ⁇ had accumulated in brain tissue. This result indicates that the accumulation level of amyloid ⁇ in the brain can be evaluated by detecting amyloid ⁇ bound to exosomes derived from brain neurons in the blood.
- the present invention it is possible to provide a technique for rapidly and highly sensitively detecting amyloid ⁇ bound to exosomes derived from brain neurons and a technique for evaluating the accumulation level of amyloid ⁇ in the brain.
- 100... complex 110... brain neuron-derived exosomes, 111... amyloid ⁇ , 112... biomarkers, 120... amyloid ⁇ -specific binding substances, 121, 151... nucleic acid fragments, 130: invasion probes, 150... exosome surface bio Marker-specific binding substance 200, 500 Fluid device 210 Substrate 220 Lid member 221 Convex part 222 Introduction port 223 Discharge port 230 Flow path 240 Well array 241 Well , 242 ... sealed well (microcompartment), L210 ... reagent solution, L220 ... sealing liquid, 242R ... well in which the signal was detected, 510 ... wall member, 810 ... flap probe, 811 ... flap site (nucleic acid fragment ), 821... second flap site (nucleic acid fragment), 820, 820'... nucleic acid fragment, F... fluorescent substance, Q... quenching substance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本願は、2021年11月4日に、日本に出願された特願2021-180612号に基づき優先権を主張し、その内容をここに援用する。
[1]血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法であって、前記血液中の脳神経細胞由来のエクソソームに結合したアミロイドβと、核酸断片で標識された、アミロイドβに特異的に結合するアミロイドβ特異的結合物質と、を結合させる工程と、前記アミロイドβ特異的結合物質を検出する工程と、を備える、検出方法。
[2]さらに、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーを検出する工程を備える、[1]に記載の検出方法。
[3]血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法であって、前記エクソソーム表面上に存在するバイオマーカーと、核酸断片で標識された、前記エクソソーム表面上に存在するバイオマーカーに特異的に結合する、エクソソーム表面上バイオマーカー特異的結合物質と、を結合させる工程と、前記血液中の脳神経細胞由来のエクソソームに結合したアミロイドβを検出する工程と、前記エクソソーム表面上バイオマーカー特異的結合物質を検出する工程と、を備える、検出方法。
[4]前記アミロイドβが、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーに結合している、[1]~[3]のいずれか一項に記載の検出方法。
[5]前記バイオマーカー又は前記アミロイドβを検出する工程が、前記バイオマーカー又は前記アミロイドβに特異的に結合する物質を用いて、前記脳神経細胞由来のエクソソームを捕捉することにより行われる、[2]~[4]のいずれか一項に記載の検出方法。
[6]前記アミロイドβ特異的結合物質が、アミロイドβに特異的に結合する抗体又は抗体断片である、[1]~[5]のいずれか一項に記載の検出方法。
[7]前記バイオマーカーが、ガングリオシドGM1である、[2]~[6]のいずれか一項に記載の検出方法。
[8]前記アミロイドβ特異的結合物質を検出する工程が、Invasive Cleavage Assayにより行われる、[1]~[7]のいずれか一項に記載の検出方法。
[9]血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キットであって、核酸断片で標識された、アミロイドβに特異的に結合するアミロイドβ特異的結合物質を含む、キット。
[10]前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーを検出する物質を更に含む、[9]に記載のキット。
[11]前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーを検出する物質が、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーに特異的に結合する物質である、[10]に記載のキット。
[12]血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キットであって、核酸断片で標識された、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーに特異的に結合する、エクソソーム表面上バイオマーカー特異的結合物質と、アミロイドβに特異的に結合するアミロイドβ特異的結合物質と、を含む、キット。
[13]前記アミロイドβ特異的結合物質が、アミロイドβに特異的に結合する抗体又は抗体断片である、[9]~[12]いずれか一項に記載のキット。
[14]前記バイオマーカーが、ガングリオシドGM1である、[10]~[13]のいずれか一項に記載のキット。
[15]脳内のアミロイドβの蓄積レベルを評価する方法であって、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβを検出する工程と、前記アミロイドβの検出量により、脳内のアミロイドβ蓄積レベルを評価する工程と、を備える、評価方法。
[16]前記脳神経細胞由来のエクソソームに結合したアミロイドβの検出が、[1]~[8]のいずれか一項に記載の検出方法により行われる、[15]に記載の評価方法。
<第1実施形態>
本発明は、一実施形態において、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法であって、前記血液中の脳神経細胞由来のエクソソームに結合したアミロイドβに、核酸断片で標識された、アミロイドβに特異的に結合するアミロイドβ特異的結合物質と、を結合させる工程と、前記アミロイドβ特異的結合物質を検出する工程と、を備える、検出方法を提供する。以下、本実施形態に係る検出方法について説明する。
生体では唾液、血液、尿、羊水、悪性腹水等の体液中で観察され、培養細胞からも分泌される。近年、エクソソームは、離れた細胞や組織に情報を伝達するための役割を担っている可能性が指摘されている。エクソソームには様々なタンパク質や脂質、核酸が含まれており、別の細胞に運搬されることによって機能的変化や生理的変化を引き起こすと考えられている。その具体例としては、感染性病原体や腫瘍に対する適応免疫応答の媒介、組織修復、神経伝達や病原性タンパク質の運搬等の役割を持つことが示唆されている。
本実施形態の検出方法においては、エクソソームは、脳神経細胞由来のエクソソームである。アルツハイマー病の原因因子と考えられているアミロイドβは、脳神経細胞由来のエクソソームに結合して運搬され、アルツハイマー病患者の脳に蓄積しプラークを形成することが知られている。そのため、脳神経細胞由来のエクソソームに結合したアミロイドβに特異的に結合する物質を利用することにより、脳神経細胞由来のエクソソームに結合したアミロイドβを検出することが可能である。
アミロイドβ111は、脳神経細胞由来のエクソソーム110の膜表面上に存在するバイオマーカー112に結合することにより、エクソソーム110に結合している。アミロイドβ111が結合可能な、脳神経細胞由来のエクソソーム110の膜表面上に存在するバイオマーカー112としては、ガングリオシドGM1等が挙げられる。
図2は、流体デバイスの一例を示す模式断面図である。図2に示すように、流体デバイス200は、基板210と、基板210に対向して配置される蓋部材220とを備えている。蓋部材220は凸部221を有しており、凸部221の先端は基板210に接している。流体デバイス200においては、ウェルアレイ240は基板210の一方面上に基板210と一体成型されており、蓋部材220と対向している。ウェルアレイ240は複数のウェル241を有する。蓋部材220は、基板210に溶着又は接着されていてもよい。
本実施形態の検出方法に用いられる流体デバイスは上述した流体デバイス200に限られない。図5は、流体デバイスの一例を示す模式断面図である。図5に示すように、流体デバイス500は、基板210と、壁部材510とを備えている。流体デバイス500においては、ウェルアレイ240は基板210の一方面上に基板210と一体成形されている。ウェルアレイ240は複数のウェル241を有する。
上述した流体デバイス200においては、蓋部材220と凸部221は一体成形されていた。しかしながら、蓋部材220と凸部221は別体として成形されていてもよい。
基板210は、例えば樹脂を用いて形成される。樹脂の種類は特に限定されないが、試薬及び封止液に対して耐性のある樹脂であることが好ましい。また、検出するシグナルが蛍光である場合には、自家蛍光が少ない樹脂であることが好ましい。例えば、シクロオレフィンポリマーや、シクロオレフィンコポリマー、シリコン、ポリプロピレン、ポリカーボネート、ポリスチレン、ポリエチレン、ポリ酢酸ビニル、フッ素樹脂、アモルファスフッ素樹脂等が挙げられるがこれらに限定されない。
続いて、場合により図2~4を参照しながら、流体デバイス200を用いた場合を例に、本実施形態の検出方法について説明する。本実施形態の検出方法は、血液中の脳神経細胞由来のエクソソーム110に結合したアミロイドβ111の検出方法であって、血液中の脳神経細胞由来のエクソソーム110に、核酸断片121で標識された、アミロイドβに特異的に結合するアミロイドβ特異的結合物質120と、を結合させる工程と、前記アミロイドβ特異的結合物質120を検出する工程と、を備える、検出方法である。本実施形態の方法によれば、脳神経細胞由来のエクソソーム110に結合したアミロイドβ111を検出することができる。
まず、図2に示すように、流体デバイス200の導入ポート222から試薬液L210を導入し、流路230に送液する。試薬液L210は、脳神経細胞由来のエクソソーム110及び核酸断片121で標識された、アミロイドβ特異的結合物質120が分散した液体であり、核酸断片121を検出するための試薬も含む。脳神経細胞由来のエクソソーム110にアミロイドβ111が結合している場合は、核酸断片121で標識された、アミロイドβ特異的結合物質120が、脳神経細胞由来のエクソソーム110に結合しているアミロイドβ111に結合する。
本実施形態によれば、例えば、核酸検出反応(例えばICA反応)に係る時間が1分~30分間程度であり、迅速な核酸検出が可能となる。
ウェル241に、脳神経細胞由来のエクソソーム110、核酸断片121で標識された、アミロイドβ特異的結合物質120等を導入した後、ウェル241の開口部を封止する工程を実施してもよい。
続いて、核酸断片121を検出する。核酸断片121の検出は、シグナル増幅反応を用いて行うことが好ましい。シグナル増幅反応としては、例えば、Invasive Cleavage Assay(ICA)が挙げられる。
本発明は、一実施形態において、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法であって、前記エクソソーム表面上に存在するバイオマーカーと、核酸断片で標識された、前記エクソソーム表面上に存在するバイオマーカーに特異的に結合する物質(エクソソーム表面上バイオマーカー特異的結合物質)と、を結合させる工程と、前記血液中の脳神経細胞由来のエクソソームに結合したアミロイドβを検出する工程と、前記エクソソーム表面上バイオマーカー特異的結合物質を検出する工程と、を備える、検出方法を提供する。以下、本実施形態に係る検出方法について説明する。
まず、図2に示すように、流体デバイス200の導入ポート222から試薬液L210を導入し、流路230に送液する。試薬液L210は、脳神経細胞由来のエクソソーム110及び核酸断片151で標識された、エクソソーム表面上バイオマーカー特異的結合物質150が分散した液体であり、核酸断片151を検出するための試薬も含む。脳神経細胞由来のエクソソーム110にアミロイドβ111が結合している場合は、エクソソーム表面上バイオマーカー特異的結合物質150は、アミロイドβ111が結合していない、脳神経細胞由来のエクソソーム110の表面上のバイオマーカー112に結合する。
固相、アミロイドβ特異的結合物質、エクソソーム表面上バイオマーカー特異的結合物質としては、前記第1実施形態に記載したものと同じものが用いられる。
本実施形態によれば、例えば、核酸検出反応(例えばICA反応)に係る時間が1分~30分間程度であり、迅速な核酸検出が可能となる。
ウェル241に、脳神経細胞由来のエクソソーム110、核酸断片151で標識された、エクソソーム表面上バイオマーカー特異的結合物質150等を導入した後の封入工程は、上記第1実施形態と同様に行うことができる。
続いて、核酸断片151を検出する。核酸断片151の検出は、核酸断片121の代わりに、核酸断片151を用いる以外は、上記第1実施形態と同様に行うことができる。
1実施形態において、本発明は、血液中の脳神経細胞由来のエクソソーム110に結合したアミロイドβ111の検出用キットであって、核酸断片121で標識された、アミロイドβの特異的結合物質120を含む、キットを提供する。
1実施形態において、本発明は、脳内のアミロイドβの蓄積レベルを評価する方法であって、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβを検出する工程と、前記アミロイドβの検出量により、脳内のアミロイドβ蓄積レベルを評価する工程と、を備える、評価方法を提供する。
<試薬調製>
(脳神経細胞由来のエクソソーム含有試料)
アミロイドβが結合した脳神経細胞由来のエクソソームを含む試料は、マウスニューロ2A(N2a)細胞に、ヒトアミロイドβ前駆体蛋白質(amyloid-β precursor protein;以下、APPとも称する)のアイソフォーム751(APP751)の遺伝子を組み込んだプラスミドを安定導入して作成した細胞をDulbecco’s Modified Eagle培地で24時間培養した培養上清を用いた。培養上清からのエクソソームの回収は超遠心分離法を用いた。具体的には、培養上清を、2000×gで10分間、10000×gで30分間、100000×gで70分間段階的に遠心分離してエクソソームを回収し、脳神経細胞由来のエクソソームを含む試料とした。血清からのエクソソームの回収は、MagCapture(登録商標)エクソソーム アイソレーションキットPS(富士フィルム和光純薬社製)を用いて行った。
コレラ毒素サブユニットB(Cholera Toxin subunit B;CTB、Sigma社製)を磁性ビーズに固定化するため、カルボキシル基修飾磁性ビーズ(Magnosphere、LC300、JSR社製)溶液に、CTBを添加し100μLに混合し、ローテーターにて30分間反応させ、さらに縮合剤EDCを加え3時間反応させ、CTBのカルボキシル磁性ビーズへの固定化を行った。
反応後未反応のCTBと試薬を取り除くため、マグネットスタンドを用いてCTB固定化カルボキシル磁性ビーズを磁気捕集、および、PBS-T(0.1%Tween20含有PBS)による洗浄を3回繰り返し、CTB固定化カルボキシル磁性ビーズ(CTBビーズ)を調製した。
抗アミロイドβ抗体修飾用及び核酸検出反応用の核酸としては、以下に示す核酸を用いた。
・DNA断片1:配列番号1に示す塩基配列を有する。
・フラッププローブ1:配列番号2に示す塩基配列を有する。
・侵入プローブ1:配列番号3に示す塩基配列を有する。
抗アミロイドβモノクローナル抗体(型式「BAN50」、富士フィルム和光純薬社製)に、配列番号1に示す塩基配列を有するDNA断片(DNA断片1)を結合させ、核酸標識抗アミロイドβ抗体を作製した。DNA断片の結合には、市販のキット(商品名「Protein-Oligo Conjugation Kit」、ソルリンク社製)を用いた。なお、核酸標識抗アミロイドβ抗体は、抗体(抗体一分子)に対して5~20倍量の核酸が修飾されるように調製した。
ICA反応による核酸修飾抗体検出を行うため、核酸検出試薬として、ICA反応試薬を調製した。本実験例におけるICA反応試薬の試薬組成は以下の通りである。
本実験例におけるICA反応試薬は、0.1μMフラッププローブ1(配列番号2)、1μM侵入プローブ1(配列番号3)、2μM FRET Cassette(FAM)(ホロジック社製)、2μM FRET Cassette(Redmond RED)(ホロジック社製)、10mM MOPS(pH7.9)、10mM MgCl2及び1000U/μLクリベースを含んでいた。
なお、これらのICA反応試薬における各成分の濃度は、本実験例1で用いたICA反応試薬における終濃度である。
CTBは、脳神経細胞由来のエクソソーム膜表面に存在するガングリオシドGM1と特異的に結合する。そのため、CTB固定化磁性ビーズを用いれば、脳神経細胞由来のエクソソームを捕捉することができる。具体的には、下記のようにして、CTB固定化磁性ビーズを用いて脳神経細胞由来のエクソソームを捕捉し、捕捉された脳神経細胞由来のエクソソームに結合したアミロイドβとアミロイドβ特異的結合物質とを結合させ、複合体を形成させた。
反応後、マグネットスタンドを用いて得られた磁性ビーズを磁気捕集し、上清の除去及び0.1%Tween含有PBS(PBS-T)を加える操作を5回繰り返して洗浄し、最後に上清を除去して複合体を得た。
得られた複合体を洗浄後にて希釈し、各反応混合液を調製した。
多数の微小のウェルを設けた基材をCOP(シクロオレフィンポリマー)で作製し、COP製の蓋材を貼合することでデバイスを作製した。1cm2あたりのウェルの総体積は0.93μLであった。計測に用いられた総ウェル数は、1000000個であった。
デバイスに、上記各反応混合液を18μL送液し、各ウェルに導入した。続いて、封止液としてFC-40(Sigma社製)を200μL送液し、各ウェルを封止した。
各反応混合溶液の送液後の上記デバイスをホットプレート上にセットし、66℃で25分間、反応させた。これにより、フラッププローブ及び侵入プローブによる、抗アミロイドβ抗体を修飾している核酸断片の認識、FENによるフラッププローブの切断、放出されたフラッププローブ断片のFRET Cassetteへの結合、FENによるFRET Cassetteの切断が進行し、Alexa488から蛍光シグナルが発せられた。
66℃で25分間加熱した後、蛍光顕微鏡(BZ-700、KEYENCE社製)で4倍の対物レンズ、GFPの蛍光フィルターを用いて、デバイスにおける各ウェルの核酸検出反応で得られる蛍光シグナルの蛍光画像を撮影した。露光時間は、3000msecとした。得らえた各反応混合液1の蛍光画像を図10に、エクソソーム濃度とデバイスのウェルに封入されたビーズの総数における蛍光シグナル数の割合(%)との関係を図11にそれぞれ示す。
<試薬調製>
(脳神経細胞由来のエクソソーム含有試料)
脳神経細胞由来のエクソソームを含む試料として、ヒト家族性変異APP遺伝子を導入した3月齢又は13月齢のマウス[ヒトAPPSw,Ind遺伝子導入マウス(J20、Jackson Laboratory社製)]の血清を用いた。血清からのエクソソームの回収は、MagCapture(登録商標)エクソソーム アイソレーションキットPS(富士フィルム和光純薬社製)を用いて行った。エクソソームを含まないコントロールとしては、PBSを用いた。
実験例1と同様にして、CTB固定化磁性ビーズ、抗アミロイドβ抗体修飾用核酸、検出用核酸、核酸修飾抗アミロイド抗体、及び、核酸検出試薬を調製した。
サンプルチューブに、6×105個のCTB固定化カルボキシル磁性ビーズ(CTBビーズ)、50、100、250μLの各マウス血清から回収されたエクソソーム又はPBS、0.1ng/mLに調整した核酸修飾抗アミロイドβ抗体を全量が100μLとなるように混合し、ローテーター上で室温1時間反応させ、複合体を形成させた。
反応後、マグネットスタンドを用いて得られた磁性ビーズを磁気捕集し、上清の除去及び0.1%Tween含有PBS(PBS-T)を加える操作を5回繰り返して洗浄し、最後に上清を除去して複合体を得た。
得られた複合体を洗浄後PBSにて希釈し、反応混合液を調製した。
実験例1に記載のデバイスを用い、実験例1と同じ手順で反応混合溶液の送液を行った。
各反応混合溶液の送液後の上記デバイスをホットプレート上にセットし、66℃で25分間、反応させた。これにより、フラッププローブ及び侵入プローブによる、抗アミロイドβ抗体を修飾している核酸断片の認識、FENによるフラッププローブの切断、放出されたフラッププローブ断片のFRET Cassetteへの結合、FENによるFRET Cassetteの切断が進行し、Alexa488から蛍光シグナルが発せられた。
66℃で25分間加熱した後、蛍光顕微鏡(BZ-700、KEYENCE社製)で4倍の対物レンズ、GFPの蛍光フィルターを用いて、デバイスにおける各ウェルの核酸検出反応で得られる蛍光シグナルの蛍光画像を撮影した。露光時間は、3000msecとした。3月齢又は13月齢のヒト家族性変異APP遺伝子導入マウス血清、及びコントロールにおける各反応混合液について測定された、デバイスのウェルに封入されたビーズの総数における蛍光シグナル数の割合(%)を図12に示した。
(マウス脳組織中のアミロイドβの検出)
実験例2で用いた3月齢又は13月齢のヒト家族性変異APP遺伝子導入マウスの脳組織を摘出し、左半球を分取し、5Mグアニジン塩酸で溶解後、Aβ ELISAキット(富士フィルム和光純薬社製)用いて、上記マウス脳組織中のアミロイドβ40及びアミロイドβ42濃度の測定を行った。また、脳組織を摘出し、右半球を4%パラホルムアルデドで一晩浸漬固定し、矢状断パラフィン切片を作製した。この切片を、抗アミロイドβモノクローナル抗体(型式「4G8」、Biolegend社製)を用いて、アミロイドβの免疫組織染色を行った。マウス脳組織中のアミロイドβ40及びアミロイドβ42濃度の測定の結果を図13に、上記マウス脳組織中のアミロイドβの免疫組織染色の結果を図14にそれぞれ示す。図13及び図14に示すように、3月齢のヒト家族性変異APP遺伝子導入マウスの脳組織には、アミロイドβは蓄積していなかったが、13月齢のヒト家族性変異APP遺伝子導入マウスの脳組織には、アミロイドβが蓄積していた。
(マウス血清中の遊離アミロイドβの検出)
Aβ ELISAキット(富士フィルム和光純薬社製)を用いて、実験例2で用いた3月齢又は13月齢のヒト家族性変異APP遺伝子導入マウス血清中の遊離のアミロイドβ40及びアミロイドβ42濃度の測定を行った。その結果を図15に示す。
図15に示したように、血清中の遊離アミロイドβは、3月齢のヒト家族性変異APP遺伝子導入マウスでも、13月齢のヒト家族性変異APP遺伝子導入マウスでも変化はなかった。この結果は、エクソソームに結合していない遊離のアミロイドβを測定することでは、脳内のアミロイドβの蓄積レベルは評価できないことを示している。
Claims (16)
- 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法であって、
前記血液中の脳神経細胞由来のエクソソームに結合したアミロイドβと、核酸断片で標識された、アミロイドβに特異的に結合するアミロイドβ特異的結合物質と、を結合させる工程と、
前記アミロイドβ特異的結合物質を検出する工程と、
を備える、検出方法。 - さらに、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーを検出する工程を備える、請求項1に記載の検出方法。
- 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法であって、
前記エクソソーム表面上に存在するバイオマーカーと、核酸断片で標識された、前記エクソソーム表面上に存在するバイオマーカーに特異的に結合する、エクソソーム表面上バイオマーカー特異的結合物質と、を結合させる工程と、
前記血液中の脳神経細胞由来のエクソソームに結合したアミロイドβを検出する工程と、
前記エクソソーム表面上バイオマーカー特異的結合物質を検出する工程と、
を備える、検出方法。 - 前記アミロイドβが、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーに結合している、請求項1~3のいずれか一項に記載の検出方法。
- 前記バイオマーカー又は前記アミロイドβを検出する工程が、前記バイオマーカー又は前記アミロイドβに特異的に結合する物質を用いて、前記脳神経細胞由来のエクソソームを捕捉することにより行われる、請求項2~4のいずれか一項に記載の検出方法。
- 前記アミロイドβ特異的結合物質が、アミロイドβに特異的に結合する抗体又は抗体断片である、請求項1~5のいずれか一項に記載の検出方法。
- 前記バイオマーカーが、ガングリオシドGM1である、請求項2~6のいずれか一項に記載の検出方法。
- 前記アミロイドβ特異的結合物質を検出する工程が、Invasive Cleavage Assayにより行われる、請求項1~7のいずれか一項に記載の検出方法。
- 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キットであって、
核酸断片で標識された、アミロイドβに特異的に結合するアミロイドβ特異的結合物質を含む、キット。 - 前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーを検出する物質を更に含む、請求項9に記載のキット。
- 前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーを検出する物質が、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーに特異的に結合する物質である、請求項10に記載のキット。
- 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キットであって、
核酸断片で標識された、前記脳神経細胞由来のエクソソーム表面上に存在するバイオマーカーに特異的に結合する、エクソソーム表面上バイオマーカー特異的結合物質と、
アミロイドβに特異的に結合するアミロイドβ特異的結合物質と、を含む、キット。 - 前記アミロイドβ特異的結合物質が、アミロイドβに特異的に結合する抗体又は抗体断片である、請求項9~12のいずれか一項に記載のキット。
- 前記バイオマーカーが、ガングリオシドGM1である、請求項10~13のいずれか一項に記載のキット。
- 脳内のアミロイドβの蓄積レベルを評価する方法であって、
血液中の脳神経細胞由来のエクソソームに結合したアミロイドβを検出する工程と、
前記アミロイドβの検出量により、脳内のアミロイドβ蓄積レベルを評価する工程と、
を備える、評価方法。 - 前記脳神経細胞由来のエクソソームに結合したアミロイドβの検出が、請求項1~8のいずれか一項に記載の検出方法により行われる、請求項15に記載の評価方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280070213.4A CN118139989A (zh) | 2021-11-04 | 2022-10-31 | 结合于血液中的脑神经细胞来源的外泌体的β淀粉样蛋白的检测方法、结合于血液中的脑神经细胞来源的外泌体的β淀粉样蛋白的检测用试剂盒、以及评价脑内的β淀粉样蛋白的蓄积水平的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021180612 | 2021-11-04 | ||
JP2021-180612 | 2021-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023080102A1 true WO2023080102A1 (ja) | 2023-05-11 |
Family
ID=86241099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/040614 WO2023080102A1 (ja) | 2021-11-04 | 2022-10-31 | 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キット、及び脳内のアミロイドβの蓄積レベルを評価する方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN118139989A (ja) |
WO (1) | WO2023080102A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054534A1 (ja) * | 2011-10-14 | 2013-04-18 | 国立大学法人北海道大学 | アミロイドβ関連の疾患用医薬及びそのスクリーニング |
WO2015115635A1 (ja) | 2014-01-31 | 2015-08-06 | 凸版印刷株式会社 | 生体分子解析キット及び生体分子解析方法 |
WO2017200070A1 (ja) * | 2016-05-19 | 2017-11-23 | 凸版印刷株式会社 | 標的分子の検出方法及び標的分子検出キット |
WO2018207906A1 (ja) * | 2017-05-12 | 2018-11-15 | 日産化学株式会社 | 基材への親和性を有するペプチド融合タンパク質 |
WO2020157705A1 (en) * | 2019-01-31 | 2020-08-06 | National University Of Singapore | Method of detecting a neurodegenerative disease |
WO2020235607A1 (ja) * | 2019-05-21 | 2020-11-26 | 凸版印刷株式会社 | 標的分子の検出方法 |
JP2021180612A (ja) | 2016-10-05 | 2021-11-18 | ラピスセミコンダクタ株式会社 | 電力伝送装置 |
-
2022
- 2022-10-31 WO PCT/JP2022/040614 patent/WO2023080102A1/ja active Application Filing
- 2022-10-31 CN CN202280070213.4A patent/CN118139989A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054534A1 (ja) * | 2011-10-14 | 2013-04-18 | 国立大学法人北海道大学 | アミロイドβ関連の疾患用医薬及びそのスクリーニング |
WO2015115635A1 (ja) | 2014-01-31 | 2015-08-06 | 凸版印刷株式会社 | 生体分子解析キット及び生体分子解析方法 |
WO2017200070A1 (ja) * | 2016-05-19 | 2017-11-23 | 凸版印刷株式会社 | 標的分子の検出方法及び標的分子検出キット |
JP2021180612A (ja) | 2016-10-05 | 2021-11-18 | ラピスセミコンダクタ株式会社 | 電力伝送装置 |
WO2018207906A1 (ja) * | 2017-05-12 | 2018-11-15 | 日産化学株式会社 | 基材への親和性を有するペプチド融合タンパク質 |
WO2020157705A1 (en) * | 2019-01-31 | 2020-08-06 | National University Of Singapore | Method of detecting a neurodegenerative disease |
WO2020235607A1 (ja) * | 2019-05-21 | 2020-11-26 | 凸版印刷株式会社 | 標的分子の検出方法 |
Non-Patent Citations (5)
Title |
---|
LAWRENCE RAJENDRAN ET AL.: "Alzheimer's disease (3-amyloid peptides are released in association with exosomes", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 30, 25 July 2006 (2006-07-25), pages 11172 - 11177, XP055447876, DOI: 10.1073/pnas.0603838103 |
MASSIMO S. FIANDACA: "Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study", ALZHEIMER'S & DEMENTIA, vol. 11, 2015, pages 600 - 607 |
OLMEDILLAS-LOPEZ S. ET AL.: "Current and Emerging Applications of Droplet Digital PCR in Oncology", MOL DIAGN THER, vol. 21, no. 5, October 2017 (2017-10-01), pages 493 - 510, XP055531296, DOI: 10.1007/s40291-017-0278-8 |
SINGH NETRAPAL, HUANG LIN, WANG DIAN-BING, SHAO NAN, ZHANG XIAN-EN: "Simultaneous Detection of a Cluster of Differentiation Markers on Leukemia-Derived Exosomes by Multiplex Immuno-Polymerase Chain Reaction via Capillary Electrophoresis Analysis", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 92, no. 15, 4 August 2020 (2020-08-04), US , pages 10569 - 10577, XP093063571, ISSN: 0003-2700, DOI: 10.1021/acs.analchem.0c01464 * |
YUYAMA KOHEI, SUN HUI, IGARASHI YASUYUKI, MONDE KENJI, HIRASE TAKUMI, NAKAYAMA MASATO, MAKINO YOICHI: "Immuno-digital invasive cleavage assay for analyzing Alzheimer’s amyloid ß-bound extracellular vesicles", ALZHEIMER'S RESEARCH & THERAPY, vol. 14, no. 1, 3 October 2022 (2022-10-03), pages 140, XP093063574, DOI: 10.1186/s13195-022-01073-w * |
Also Published As
Publication number | Publication date |
---|---|
CN118139989A (zh) | 2024-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8846415B2 (en) | Ultra-sensitive detection of molecules on single molecule arrays | |
JP5860922B2 (ja) | ビーズまたは他の捕捉物を用いた分子または粒子の超高感度検出 | |
EP3460474B1 (en) | Method and kit for target molecule detection | |
JP5816291B2 (ja) | 生体分子分析方法及び生体分子分析装置 | |
US20100075355A1 (en) | Ultra-sensitive detection of enzymes by capture-and-release followed by quantification | |
US20100075439A1 (en) | Ultra-sensitive detection of molecules by capture-and-release using reducing agents followed by quantification | |
US11898194B2 (en) | Method for detecting target molecule | |
US20140011691A1 (en) | Morphology and protein specific reagents as diagnostics for neurodegenerative diseases | |
AU2010206657A1 (en) | Apparatus and methods for detecting inflammation using quantum dots | |
WO2017134906A1 (ja) | 検体検出用装置及び検体検出方法 | |
US20220106648A1 (en) | Method for detecting target molecule | |
CN101115985A (zh) | 光谱分析单粒子的系统和方法 | |
US20220397528A1 (en) | Systems and methods for rapid, sensitive multiplex immunoassays | |
WO2023080102A1 (ja) | 血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出方法、血液中の脳神経細胞由来のエクソソームに結合したアミロイドβの検出用キット、及び脳内のアミロイドβの蓄積レベルを評価する方法 | |
JP2023521872A (ja) | 細胞外小胞の光学信号を増強する方法およびシステム | |
WO2010039179A1 (en) | Ultra-sensitive detection of molecules or enzymes | |
US20230221319A1 (en) | A Method, A System, An Article, A Kit And Use Thereof For Biomolecule, Bioorganelle, Bioparticle, Cell And Microorganism Detection | |
JP6309950B2 (ja) | 標的成分を持つ試料流体の処理 | |
US20230167492A1 (en) | Molecular detection via assembly of particle complexes | |
JP7503817B2 (ja) | 分析デバイス | |
TW202018296A (zh) | 癌幹細胞之生物標誌 | |
WO2024085141A1 (ja) | 流体デバイス及び標的分子の検出方法 | |
Zhang | Characterisation of neurodegenerative diseases derived protein aggregates using improved single-molecule pull-down |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22889922 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023558022 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022889922 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022889922 Country of ref document: EP Effective date: 20240604 |